These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29122536)

  • 21. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Ogura M; Ando K; Suzuki T; Ishizawa K; Oh SY; Itoh K; Yamamoto K; Au WY; Tien HF; Matsuno Y; Terauchi T; Yamamoto K; Mori M; Tanaka Y; Shimamoto T; Tobinai K; Kim WS
    Br J Haematol; 2014 Jun; 165(6):768-76. PubMed ID: 24617454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.
    Du J; Yu D; Han X; Zhu L; Huang Z
    JAMA Netw Open; 2021 May; 4(5):e219807. PubMed ID: 34042995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
    Wang M; Popplewell LL; Collins RH; Winter JN; Goy A; Kaminski MS; Bartlett NL; Johnston PB; Lister J; Fanning SR; Tuscano JM; Beck JT; Kaya H; Robeva A; Fan J; Klimovsky J; Cheung W; Cherfi A; O'Connor OA
    Br J Haematol; 2014 May; 165(4):510-8. PubMed ID: 24579926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
    Schulz H; Bohlius J; Skoetz N; Trelle S; Kober T; Reiser M; Dreyling M; Herold M; Schwarzer G; Hallek M; Engert A
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003805. PubMed ID: 17943799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
    Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS
    Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
    Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
    Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.
    Mussetti A; Kumar A; Dahi PB; Perales MA; Sauter CS
    Blood Rev; 2015 May; 29(3):143-52. PubMed ID: 25468719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis.
    Hilal T; Wang Z; Almader-Douglas D; Rosenthal A; Reeder CB; Jain T
    Am J Hematol; 2018 Oct; 93(10):1220-1226. PubMed ID: 30033656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
    Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
    Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
    Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
    Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
    Ng ZY; Bishton M; Ritchie D; Campbell R; Gilbertson M; Hill K; Ratnasingam S; Schwarer A; Manos K; Shorten S; Ng M; Nelson N; Xin L; De Mel Widanalage S; Sunny T; Purtill D; Poon M; Johnston A; Cochrane T; Lee HP; Hapgood G; Tam C; Opat S; Hawkes E; Seymour J; Cheah CY
    Hematol Oncol; 2019 Aug; 37(3):253-260. PubMed ID: 30983008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib for the treatment of multiple myeloma.
    Scott K; Hayden PJ; Will A; Wheatley K; Coyne I
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD010816. PubMed ID: 27096326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis.
    Roufarshbaf M; Javeri M; Akbari V; Matin PH; Farrokhi P; Sadeghi E; Heidari Z; Moghaddas A
    Daru; 2022 Dec; 30(2):367-378. PubMed ID: 36057010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.